RxDoctor Payments Data

Sean Sachdev

Radiation Oncology · Chicago, ILNPI 1558640300

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $21,719 of the $34,477 with a category attached, or 63.0%. 10 manufacturers reported payments, led by Pfizer at 45.6% of the total. Reporting peaked in 2024 at $28,983 and has fallen 92.8% since, to $2,100 in 2025. Among radiation oncology clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$34,477in general payments, 2019–2025

Across 37 payments — averaging $931.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$16K
  • Servier Pharmaceuticals LLC$14K
  • Astellas Pharma Global Development$2K
  • Telix Pharmaceuticals$1K
  • Astellas Pharma US Inc$861
  • AstraZeneca$318
  • plus $729 from 4 others
$132,227in research payments, 2019–2025

Across 24 payments — averaging $5509.45 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Progenics Pharmaceuticals, Inc.$132K

What the payments were for

  • Consulting fees$21,71963%
  • Speaking & faculty fees$5,93817%
  • Travel & lodging$4,32613%
  • Food & beverage$2,4957%

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$34,477 in reported general payments places this provider in the 95th percentile of 242 radiation oncology providers in Illinois.

See all radiation oncology providers in Illinois

Medicare billing

Part B allowed, 2024
$345,909
Medicare patients
255
Services billed
3,666

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OrgovyxRelugolix77$205,099
Tamsulosin Hcl119$1,469
Finasteride14$194

Paid to pharmacies, not to this prescriber.

Other radiation oncology in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →